Effect of platinum based dual drug secondline therapy on prognosis of NSCLC patients and relative factors analysis

doi:10.3760/cma.j.issn.1673422X.2018.05.003

Abstract

Abstract: ObjectiveTo analyze the prognostic implications of secondline double drug regimens for advanced nonsmall cell lung cancer (NSCLC) patients and related factors. MethodsEighty patients with advanced NSCLC who were accepted from January 2014 to December 2016 in our hospital were chosen as the research objects. The patients were randomly divided into two groups using the random number table method, namely single drug group (n=40) and double drug group (n=40). The patients in single drug group were treated with docetaxel or pemetrexed, and the patients in double drug group were treated with docetaxel, pemetrexed, vinorelbine or paclitaxel combined with platinum (cisplatin). The effects of patients in the two groups were compared and the factors affecting the prognosis of the patients were analyzed. ResultsThe remission rate in the double drug group was significantly higher than that in the single drug group (45.0% vs. 20.0%; χ2=4.493, P=0.021). The results of single factor analysis for patients in double drug group showed that pathological type (χ2=7.511, P=0.023), time from firstline treatment to secondline treatment (χ2=6.412, P=0.041), secondline baseline TNM stage (χ2=4.022，P=0.045), secondline cycle number (χ2=5.065，P=0.027), leukopenia (χ2=4.852, P=0.033) and neuron specific enolase (χ2=9.243, P=0.002) were the main prognostic factors of the secondline chemotherapy. The results of multivariate analysis for patients in double drug group showed that time from firstline treatment to secondline treatment (OR=3.511, 95%CI: 1.4863.602, P=0.033), secondline baseline TNM stage (OR=1.623, 95%CI: 1.1272.119, P=0.027), secondline cycle number (OR=2.208, 95%CI: 1.5892.827, P=0.014) and neuron specific enolase (OR=1.960, 95%CI: 1.2092.773, P=0.025) were independent prognostic factors. ConclusionThe remission effect of double secondline treatment scheme based on platinum for patients with NSCLC is good, and the time form firstline treatment to secondline treatment, secondline baseline TNM stage, secondline cycle number and neuron specific enolase are independent prognostic factors.

Key words: Carcinoma, non-small-cell lung, Drug therapy, Platinum compounds, Antineoplastic combined chemotherapy protocols, Influencing factors

Wang Dazhong. Effect of platinum based dual drug secondline therapy on prognosis of NSCLC patients and relative factors analysis[J]. Journal of International Oncology, 2018, 45(5): 269-272.

References

［1］白丽艳, 祁玉娟. 晚期非小细胞肺癌化疗新进展［J］. 中国现代医药杂志, 2016, 18(7): 99102. DOI: 10.3969/j.issn.16729463.2016.07.035. ［2］程春来. 化疗联合DCCIK方案治疗非小细胞肺癌的疗效分析［J］. 实用癌症杂志, 2015, 30(5): 759761. DOI: 10.3969/j.issn.10015930.2015.05.040. ［3］ Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase Ⅱ study of gefitinib for chemotherapynaive patients with advanced nonsmallcell lung cancer with epidermal growth factor receptor gene mutations［J］. J Clin Oncol, 2006, 24(21): 33403346. DOI: 10.1200/JCO.2005.05.4692. ［4］ Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmallcell lung cancer previously treated with chemotherapy［J］. J Clin Oncol, 2004, 22(9): 15891597. DOI: 10.1200/JCO.2004.08.163. ［5］吴姗姗, 严峰, 邓玉玲, 等. 小细胞和非小细胞肺癌晚期患者CD3+ CD4+及CD3+ CD8+ T淋巴细胞亚群的差异［J］. 中国免疫学杂志, 2015, 31(1): 114116, 121. DOI: 10.3969/j.issn.1000484X.2015.01.024. ［6］王恩华, 朱明华, 步宏, 等. 非小细胞肺癌靶向药物治疗相关基因检测的规范建议［J］. 中华病理学杂志, 2016, 45(2): 7377. DOI: 10.3760/cma.j.issn.05295807.2016.02.001. ［7］崔月倩, 胡毅. 依维莫司联合化疗或靶向药物治疗晚期非小细胞肺癌的临床疗效和安全性［J］. 现代肿瘤医学, 2016, 24(24): 39203923. DOI: 10.3969/j.issn.16724992.2016.24.011. ［8］郑积华, 林金容, 谢波, 等. 培美曲塞与多西他赛二线随机分组治疗晚期非小细胞肺癌对比分析［J］. 中华肿瘤防治杂志, 2013, 20(5): 368370. DOI: 10.16073/j.cnki.cjcpt.2013.05.016. ［9］ Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmallcell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer)［J］. Lancet, 2005, 366(9496): 15271537. DOI: 10.1016/S01406736(05)676258. ［10］金静思, 贺巾钊, 周黎明. 非小细胞肺癌分子靶向治疗药物的现状及进展［J］. 中国肿瘤临床, 2015, 42(17): 881885. DOI: 10.3969/j.issn.10008179.2015.17.714. ［11］ Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in nonsmallcell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials［J］. J Clin Oncol, 2005, 23(31): 80818092. DOI: 10.1200/JCO.2005.02.7078. ［12］姜忠于, 胡春秀, 刘学武, 等. 靶向药物治疗对表皮生长因子受体基因不同位点突变的非小细胞肺癌患者预后影响［J］. 中国临床药理学杂志, 2015, 31(23): 23062308. DOI: 10.13699/j.cnki.10016821.2015.23.009. ［13］林动, 许凌, 林景辉, 等. 埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌的疗效观察［J］. 实用肿瘤杂志, 2015, 30(3): 220224. DOI: 10.13267/j.cnki.syzlzz.2015.03.007. ［14］ Miller VA. Optimizing therapy in previously treated nonsmall cell lung cancer［J］. Semin Oncol, 2006, 33(1 Supple 1): S2531. DOI: 10.1053/j.seminoncol.2005.12.005. ［15］王宝强, 周陈华. 紫杉醇联合顺铂同步放化疗治疗局部晚期非小细胞肺癌的临床疗效及安全性评价［J］. 中国临床药理学杂志, 2015, 31(8): 603605. DOI: 10.13699/j.cnki.10016821.2015.08.006. ［16］马亚梅. 培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效观察［J］. 实用癌症杂志, 2015, 30(2): 205207. DOI: 10.3969/j.issn.10015930.2015.02.015. ［17］孔倩, 王心悦, 蒋日成, 等. 不同二线方案治疗178例晚期非小细胞肺癌的预后及影响因素［J］. 中华肿瘤杂志, 2016, 38(4): 294299. DOI: 10.3760/cma.j.issn.02533766.2016.04.010.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[4]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[5]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui. Research progress of Nrf2 in ovarian cancer [J]. Journal of International Oncology, 2023, 50(8): 493-497.
[6]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[7]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[8]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[9]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[10]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[11]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[12]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng. Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(11): 665-670.
[13]	Tao Jie, Wu Mei, Zhang Yan. Efficacy and influencing factors of anlotinib in treatment of elderly patients with small cell lung cancer after second-line treatment failure [J]. Journal of International Oncology, 2022, 49(1): 39-44.
[14]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[15]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer [J]. Journal of International Oncology, 2021, 48(5): 302-307.